▶ 調査レポート

世界のアンチセンスオリゴヌクレオチド(ASO)市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Antisense Oligonucleotides Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界のアンチセンスオリゴヌクレオチド(ASO)市場規模・現状・予測(2021年-2027年) / Global Antisense Oligonucleotides Market Size, Status and Forecast 2021-2027 / QFJ1-3837資料のイメージです。• レポートコード:QFJ1-3837
• 出版社/出版日:QYResearch / 2021年6月
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、123ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User¥865,800 (USD5,850)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査レポートでは、アンチセンスオリゴヌクレオチド(ASO)の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(RNAアンチセンスオリゴヌクレオチド、DNAアンチセンスオリゴヌクレオチド)、用途別市場規模(病院、診療所、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・アンチセンスオリゴヌクレオチド(ASO)の市場動向
・企業の競争状況、市場シェア
・アンチセンスオリゴヌクレオチド(ASO)の種類別市場規模と予測2016-2027(RNAアンチセンスオリゴヌクレオチド、DNAアンチセンスオリゴヌクレオチド)
・アンチセンスオリゴヌクレオチド(ASO)の用途別市場規模と予測2016-2027(病院、診療所、その他)
・アンチセンスオリゴヌクレオチド(ASO)の北米市場規模2016-2027(アメリカ、カナダ)
・アンチセンスオリゴヌクレオチド(ASO)の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・アンチセンスオリゴヌクレオチド(ASO)のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・アンチセンスオリゴヌクレオチド(ASO)の中南米市場規模2016-2027(メキシコ、ブラジル)
・アンチセンスオリゴヌクレオチド(ASO)の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Ionis Pharmaceuticals、Sarepta Therapeutics、Biogen、Alnylam Pharmaceuticals、Antisense Therapeutics、Isarna Therapeutics、Arrowhead Pharmaceuticals、Atlantic Pharmaceuticals、Enzon Pharmaceuticals、Bio-Path Holdings、GlaxoSmithKline、Geron、ICO Therapeutics、Marina Biotech、RXi Pharmaceuticals)
・結論

Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein.

Market Analysis and Insights: Global Antisense Oligonucleotides Market
The global Antisense Oligonucleotides market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense Oligonucleotides market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense Oligonucleotides market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense Oligonucleotides market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense Oligonucleotides market.

Global Antisense Oligonucleotides Scope and Market Size
Antisense Oligonucleotides market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antisense Oligonucleotides market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
RNA Antisense Oligonucleotides
DNA Antisense Oligonucleotides

Segment by Application
Hospitals
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Biogen
Alnylam Pharmaceuticals
Antisense Therapeutics
Isarna Therapeutics
Arrowhead Pharmaceuticals
Atlantic Pharmaceuticals
Enzon Pharmaceuticals
Bio-Path Holdings
GlaxoSmithKline
Geron
ICO Therapeutics
Marina Biotech
RXi Pharmaceuticals

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotides Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 RNA Antisense Oligonucleotides
1.2.3 DNA Antisense Oligonucleotides
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotides Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Antisense Oligonucleotides Market Perspective (2016-2027)
2.2 Antisense Oligonucleotides Growth Trends by Regions
2.2.1 Antisense Oligonucleotides Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Antisense Oligonucleotides Historic Market Share by Regions (2016-2021)
2.2.3 Antisense Oligonucleotides Forecasted Market Size by Regions (2022-2027)
2.3 Antisense Oligonucleotides Industry Dynamic
2.3.1 Antisense Oligonucleotides Market Trends
2.3.2 Antisense Oligonucleotides Market Drivers
2.3.3 Antisense Oligonucleotides Market Challenges
2.3.4 Antisense Oligonucleotides Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotides Players by Revenue
3.1.1 Global Top Antisense Oligonucleotides Players by Revenue (2016-2021)
3.1.2 Global Antisense Oligonucleotides Revenue Market Share by Players (2016-2021)
3.2 Global Antisense Oligonucleotides Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Antisense Oligonucleotides Revenue
3.4 Global Antisense Oligonucleotides Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotides Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotides Revenue in 2020
3.5 Antisense Oligonucleotides Key Players Head office and Area Served
3.6 Key Players Antisense Oligonucleotides Product Solution and Service
3.7 Date of Enter into Antisense Oligonucleotides Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Antisense Oligonucleotides Breakdown Data by Type
4.1 Global Antisense Oligonucleotides Historic Market Size by Type (2016-2021)
4.2 Global Antisense Oligonucleotides Forecasted Market Size by Type (2022-2027)

5 Antisense Oligonucleotides Breakdown Data by Application
5.1 Global Antisense Oligonucleotides Historic Market Size by Application (2016-2021)
5.2 Global Antisense Oligonucleotides Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Antisense Oligonucleotides Market Size (2016-2027)
6.2 North America Antisense Oligonucleotides Market Size by Type
6.2.1 North America Antisense Oligonucleotides Market Size by Type (2016-2021)
6.2.2 North America Antisense Oligonucleotides Market Size by Type (2022-2027)
6.2.3 North America Antisense Oligonucleotides Market Size by Type (2016-2027)
6.3 North America Antisense Oligonucleotides Market Size by Application
6.3.1 North America Antisense Oligonucleotides Market Size by Application (2016-2021)
6.3.2 North America Antisense Oligonucleotides Market Size by Application (2022-2027)
6.3.3 North America Antisense Oligonucleotides Market Size by Application (2016-2027)
6.4 North America Antisense Oligonucleotides Market Size by Country
6.4.1 North America Antisense Oligonucleotides Market Size by Country (2016-2021)
6.4.2 North America Antisense Oligonucleotides Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Antisense Oligonucleotides Market Size (2016-2027)
7.2 Europe Antisense Oligonucleotides Market Size by Type
7.2.1 Europe Antisense Oligonucleotides Market Size by Type (2016-2021)
7.2.2 Europe Antisense Oligonucleotides Market Size by Type (2022-2027)
7.2.3 Europe Antisense Oligonucleotides Market Size by Type (2016-2027)
7.3 Europe Antisense Oligonucleotides Market Size by Application
7.3.1 Europe Antisense Oligonucleotides Market Size by Application (2016-2021)
7.3.2 Europe Antisense Oligonucleotides Market Size by Application (2022-2027)
7.3.3 Europe Antisense Oligonucleotides Market Size by Application (2016-2027)
7.4 Europe Antisense Oligonucleotides Market Size by Country
7.4.1 Europe Antisense Oligonucleotides Market Size by Country (2016-2021)
7.4.2 Europe Antisense Oligonucleotides Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotides Market Size (2016-2027)
8.2 Asia-Pacific Antisense Oligonucleotides Market Size by Type
8.2.1 Asia-Pacific Antisense Oligonucleotides Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Antisense Oligonucleotides Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Antisense Oligonucleotides Market Size by Type (2016-2027)
8.3 Asia-Pacific Antisense Oligonucleotides Market Size by Application
8.3.1 Asia-Pacific Antisense Oligonucleotides Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Antisense Oligonucleotides Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Antisense Oligonucleotides Market Size by Application (2016-2027)
8.4 Asia-Pacific Antisense Oligonucleotides Market Size by Region
8.4.1 Asia-Pacific Antisense Oligonucleotides Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Antisense Oligonucleotides Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Antisense Oligonucleotides Market Size (2016-2027)
9.2 Latin America Antisense Oligonucleotides Market Size by Type
9.2.1 Latin America Antisense Oligonucleotides Market Size by Type (2016-2021)
9.2.2 Latin America Antisense Oligonucleotides Market Size by Type (2022-2027)
9.2.3 Latin America Antisense Oligonucleotides Market Size by Type (2016-2027)
9.3 Latin America Antisense Oligonucleotides Market Size by Application
9.3.1 Latin America Antisense Oligonucleotides Market Size by Application (2016-2021)
9.3.2 Latin America Antisense Oligonucleotides Market Size by Application (2022-2027)
9.3.3 Latin America Antisense Oligonucleotides Market Size by Application (2016-2027)
9.4 Latin America Antisense Oligonucleotides Market Size by Country
9.4.1 Latin America Antisense Oligonucleotides Market Size by Country (2016-2021)
9.4.2 Latin America Antisense Oligonucleotides Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotides Market Size (2016-2027)
10.2 Middle East & Africa Antisense Oligonucleotides Market Size by Type
10.2.1 Middle East & Africa Antisense Oligonucleotides Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Antisense Oligonucleotides Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Antisense Oligonucleotides Market Size by Type (2016-2027)
10.3 Middle East & Africa Antisense Oligonucleotides Market Size by Application
10.3.1 Middle East & Africa Antisense Oligonucleotides Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Antisense Oligonucleotides Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Antisense Oligonucleotides Market Size by Application (2016-2027)
10.4 Middle East & Africa Antisense Oligonucleotides Market Size by Country
10.4.1 Middle East & Africa Antisense Oligonucleotides Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Antisense Oligonucleotides Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Details
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotides Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Details
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotides Introduction
11.2.4 Sarepta Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen Antisense Oligonucleotides Introduction
11.3.4 Biogen Revenue in Antisense Oligonucleotides Business (2016-2021)
11.3.5 Biogen Recent Development
11.4 Alnylam Pharmaceuticals
11.4.1 Alnylam Pharmaceuticals Company Details
11.4.2 Alnylam Pharmaceuticals Business Overview
11.4.3 Alnylam Pharmaceuticals Antisense Oligonucleotides Introduction
11.4.4 Alnylam Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.4.5 Alnylam Pharmaceuticals Recent Development
11.5 Antisense Therapeutics
11.5.1 Antisense Therapeutics Company Details
11.5.2 Antisense Therapeutics Business Overview
11.5.3 Antisense Therapeutics Antisense Oligonucleotides Introduction
11.5.4 Antisense Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021)
11.5.5 Antisense Therapeutics Recent Development
11.6 Isarna Therapeutics
11.6.1 Isarna Therapeutics Company Details
11.6.2 Isarna Therapeutics Business Overview
11.6.3 Isarna Therapeutics Antisense Oligonucleotides Introduction
11.6.4 Isarna Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021)
11.6.5 Isarna Therapeutics Recent Development
11.7 Arrowhead Pharmaceuticals
11.7.1 Arrowhead Pharmaceuticals Company Details
11.7.2 Arrowhead Pharmaceuticals Business Overview
11.7.3 Arrowhead Pharmaceuticals Antisense Oligonucleotides Introduction
11.7.4 Arrowhead Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.7.5 Arrowhead Pharmaceuticals Recent Development
11.8 Atlantic Pharmaceuticals
11.8.1 Atlantic Pharmaceuticals Company Details
11.8.2 Atlantic Pharmaceuticals Business Overview
11.8.3 Atlantic Pharmaceuticals Antisense Oligonucleotides Introduction
11.8.4 Atlantic Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.8.5 Atlantic Pharmaceuticals Recent Development
11.9 Enzon Pharmaceuticals
11.9.1 Enzon Pharmaceuticals Company Details
11.9.2 Enzon Pharmaceuticals Business Overview
11.9.3 Enzon Pharmaceuticals Antisense Oligonucleotides Introduction
11.9.4 Enzon Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.9.5 Enzon Pharmaceuticals Recent Development
11.10 Bio-Path Holdings
11.10.1 Bio-Path Holdings Company Details
11.10.2 Bio-Path Holdings Business Overview
11.10.3 Bio-Path Holdings Antisense Oligonucleotides Introduction
11.10.4 Bio-Path Holdings Revenue in Antisense Oligonucleotides Business (2016-2021)
11.10.5 Bio-Path Holdings Recent Development
11.11 GlaxoSmithKline
11.11.1 GlaxoSmithKline Company Details
11.11.2 GlaxoSmithKline Business Overview
11.11.3 GlaxoSmithKline Antisense Oligonucleotides Introduction
11.11.4 GlaxoSmithKline Revenue in Antisense Oligonucleotides Business (2016-2021)
11.11.5 GlaxoSmithKline Recent Development
11.12 Geron
11.12.1 Geron Company Details
11.12.2 Geron Business Overview
11.12.3 Geron Antisense Oligonucleotides Introduction
11.12.4 Geron Revenue in Antisense Oligonucleotides Business (2016-2021)
11.12.5 Geron Recent Development
11.13 ICO Therapeutics
11.13.1 ICO Therapeutics Company Details
11.13.2 ICO Therapeutics Business Overview
11.13.3 ICO Therapeutics Antisense Oligonucleotides Introduction
11.13.4 ICO Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021)
11.13.5 ICO Therapeutics Recent Development
11.14 Marina Biotech
11.14.1 Marina Biotech Company Details
11.14.2 Marina Biotech Business Overview
11.14.3 Marina Biotech Antisense Oligonucleotides Introduction
11.14.4 Marina Biotech Revenue in Antisense Oligonucleotides Business (2016-2021)
11.14.5 Marina Biotech Recent Development
11.15 RXi Pharmaceuticals
11.15.1 RXi Pharmaceuticals Company Details
11.15.2 RXi Pharmaceuticals Business Overview
11.15.3 RXi Pharmaceuticals Antisense Oligonucleotides Introduction
11.15.4 RXi Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021)
11.15.5 RXi Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Antisense Oligonucleotides Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of RNA Antisense Oligonucleotides
Table 3. Key Players of DNA Antisense Oligonucleotides
Table 4. Global Antisense Oligonucleotides Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Antisense Oligonucleotides Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Antisense Oligonucleotides Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Antisense Oligonucleotides Market Share by Regions (2016-2021)
Table 8. Global Antisense Oligonucleotides Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Antisense Oligonucleotides Market Share by Regions (2022-2027)
Table 10. Antisense Oligonucleotides Market Trends
Table 11. Antisense Oligonucleotides Market Drivers
Table 12. Antisense Oligonucleotides Market Challenges
Table 13. Antisense Oligonucleotides Market Restraints
Table 14. Global Antisense Oligonucleotides Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Antisense Oligonucleotides Market Share by Players (2016-2021)
Table 16. Global Top Antisense Oligonucleotides Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense Oligonucleotides as of 2020)
Table 17. Ranking of Global Top Antisense Oligonucleotides Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Antisense Oligonucleotides Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Antisense Oligonucleotides Product Solution and Service
Table 21. Date of Enter into Antisense Oligonucleotides Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Antisense Oligonucleotides Revenue Market Share by Type (2016-2021)
Table 25. Global Antisense Oligonucleotides Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Antisense Oligonucleotides Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Antisense Oligonucleotides Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Antisense Oligonucleotides Revenue Market Share by Application (2016-2021)
Table 29. Global Antisense Oligonucleotides Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Antisense Oligonucleotides Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Antisense Oligonucleotides Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Antisense Oligonucleotides Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Antisense Oligonucleotides Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Antisense Oligonucleotides Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Antisense Oligonucleotides Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Antisense Oligonucleotides Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Antisense Oligonucleotides Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Antisense Oligonucleotides Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Antisense Oligonucleotides Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Antisense Oligonucleotides Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Antisense Oligonucleotides Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Antisense Oligonucleotides Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Antisense Oligonucleotides Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Antisense Oligonucleotides Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Antisense Oligonucleotides Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Antisense Oligonucleotides Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Antisense Oligonucleotides Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Antisense Oligonucleotides Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Antisense Oligonucleotides Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Antisense Oligonucleotides Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Antisense Oligonucleotides Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Antisense Oligonucleotides Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Antisense Oligonucleotides Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Antisense Oligonucleotides Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Antisense Oligonucleotides Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Antisense Oligonucleotides Market Size by Country (2022-2027) & (US$ Million)
Table 61. Ionis Pharmaceuticals Company Details
Table 62. Ionis Pharmaceuticals Business Overview
Table 63. Ionis Pharmaceuticals Antisense Oligonucleotides Product
Table 64. Ionis Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 65. Ionis Pharmaceuticals Recent Development
Table 66. Sarepta Therapeutics Company Details
Table 67. Sarepta Therapeutics Business Overview
Table 68. Sarepta Therapeutics Antisense Oligonucleotides Product
Table 69. Sarepta Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 70. Sarepta Therapeutics Recent Development
Table 71. Biogen Company Details
Table 72. Biogen Business Overview
Table 73. Biogen Antisense Oligonucleotides Product
Table 74. Biogen Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 75. Biogen Recent Development
Table 76. Alnylam Pharmaceuticals Company Details
Table 77. Alnylam Pharmaceuticals Business Overview
Table 78. Alnylam Pharmaceuticals Antisense Oligonucleotides Product
Table 79. Alnylam Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 80. Alnylam Pharmaceuticals Recent Development
Table 81. Antisense Therapeutics Company Details
Table 82. Antisense Therapeutics Business Overview
Table 83. Antisense Therapeutics Antisense Oligonucleotides Product
Table 84. Antisense Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 85. Antisense Therapeutics Recent Development
Table 86. Isarna Therapeutics Company Details
Table 87. Isarna Therapeutics Business Overview
Table 88. Isarna Therapeutics Antisense Oligonucleotides Product
Table 89. Isarna Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 90. Isarna Therapeutics Recent Development
Table 91. Arrowhead Pharmaceuticals Company Details
Table 92. Arrowhead Pharmaceuticals Business Overview
Table 93. Arrowhead Pharmaceuticals Antisense Oligonucleotides Product
Table 94. Arrowhead Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 95. Arrowhead Pharmaceuticals Recent Development
Table 96. Atlantic Pharmaceuticals Company Details
Table 97. Atlantic Pharmaceuticals Business Overview
Table 98. Atlantic Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 99. Atlantic Pharmaceuticals Recent Development
Table 100. Enzon Pharmaceuticals Company Details
Table 101. Enzon Pharmaceuticals Business Overview
Table 102. Enzon Pharmaceuticals Antisense Oligonucleotides Product
Table 103. Enzon Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 104. Enzon Pharmaceuticals Recent Development
Table 105. Bio-Path Holdings Company Details
Table 106. Bio-Path Holdings Business Overview
Table 107. Bio-Path Holdings Antisense Oligonucleotides Product
Table 108. Bio-Path Holdings Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 109. Bio-Path Holdings Recent Development
Table 110. GlaxoSmithKline Company Details
Table 111. GlaxoSmithKline Business Overview
Table 112. GlaxoSmithKline Antisense Oligonucleotides Product
Table 113. GlaxoSmithKline Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 114. GlaxoSmithKline Recent Development
Table 115. Geron Company Details
Table 116. Geron Business Overview
Table 117. Geron Antisense Oligonucleotides Product
Table 118. Geron Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 119. Geron Recent Development
Table 120. ICO Therapeutics Company Details
Table 121. ICO Therapeutics Business Overview
Table 122. ICO Therapeutics Antisense Oligonucleotides Product
Table 123. ICO Therapeutics Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 124. ICO Therapeutics Recent Development
Table 125. Marina Biotech Company Details
Table 126. Marina Biotech Business Overview
Table 127. Marina Biotech Antisense Oligonucleotides Product
Table 128. Marina Biotech Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 129. Marina Biotech Recent Development
Table 130. RXi Pharmaceuticals Company Details
Table 131. RXi Pharmaceuticals Business Overview
Table 132. RXi Pharmaceuticals Antisense Oligonucleotides Product
Table 133. RXi Pharmaceuticals Revenue in Antisense Oligonucleotides Business (2016-2021) & (US$ Million)
Table 134. RXi Pharmaceuticals Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense Oligonucleotides Market Share by Type: 2020 VS 2027
Figure 2. RNA Antisense Oligonucleotides Features
Figure 3. DNA Antisense Oligonucleotides Features
Figure 4. Global Antisense Oligonucleotides Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Antisense Oligonucleotides Report Years Considered
Figure 9. Global Antisense Oligonucleotides Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Antisense Oligonucleotides Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Antisense Oligonucleotides Market Share by Regions: 2020 VS 2027
Figure 12. Global Antisense Oligonucleotides Market Share by Regions (2022-2027)
Figure 13. Global Antisense Oligonucleotides Market Share by Players in 2020
Figure 14. Global Top Antisense Oligonucleotides Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antisense Oligonucleotides as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Antisense Oligonucleotides Revenue in 2020
Figure 16. Global Antisense Oligonucleotides Revenue Market Share by Type (2016-2021)
Figure 17. Global Antisense Oligonucleotides Revenue Market Share by Type (2022-2027)
Figure 18. North America Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Antisense Oligonucleotides Market Share by Type (2016-2027)
Figure 20. North America Antisense Oligonucleotides Market Share by Application (2016-2027)
Figure 21. North America Antisense Oligonucleotides Market Share by Country (2016-2027)
Figure 22. United States Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Antisense Oligonucleotides Market Share by Type (2016-2027)
Figure 26. Europe Antisense Oligonucleotides Market Share by Application (2016-2027)
Figure 27. Europe Antisense Oligonucleotides Market Share by Country (2016-2027)
Figure 28. Germany Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Antisense Oligonucleotides Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Antisense Oligonucleotides Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Antisense Oligonucleotides Market Share by Region (2016-2027)
Figure 38. China Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Antisense Oligonucleotides Market Share by Type (2016-2027)
Figure 46. Latin America Antisense Oligonucleotides Market Share by Application (2016-2027)
Figure 47. Latin America Antisense Oligonucleotides Market Share by Country (2016-2027)
Figure 48. Mexico Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Antisense Oligonucleotides Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Antisense Oligonucleotides Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Antisense Oligonucleotides Market Share by Country (2016-2027)
Figure 54. Turkey Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Antisense Oligonucleotides Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Ionis Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 58. Sarepta Therapeutics Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 59. Biogen Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 60. Alnylam Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 61. Antisense Therapeutics Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 62. Isarna Therapeutics Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 63. Arrowhead Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 64. Atlantic Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 65. Enzon Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 66. Bio-Path Holdings Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 67. GlaxoSmithKline Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 68. Geron Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 69. ICO Therapeutics Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 70. Marina Biotech Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 71. RXi Pharmaceuticals Revenue Growth Rate in Antisense Oligonucleotides Business (2016-2021)
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed